Eesti -
eesti -
Ravimiamet
aritavi gastroresistentne kõvakapsel
actavis group ptc ehf. - duloksetiin - gastroresistentne kõvakapsel - 60mg 30tk; 60mg 90tk; 60mg 7tk; 60mg 10tk; 60mg 14tk; 60mg 60tk; 60mg 100tk; 60mg 56tk; 60mg 84tk
Eesti -
eesti -
Ravimiamet
aritavi gastroresistentne kõvakapsel
actavis group ptc ehf. - duloksetiin - gastroresistentne kõvakapsel - 30mg 56tk; 30mg 84tk; 30mg 90tk; 30mg 14tk; 30mg 10tk; 30mg 98tk; 30mg 28tk; 30mg 60tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
bimzelx
ucb pharma s.a. - bimekizumab - psoriaas - immunosupressandid - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
cablivi
ablynx nv - caplacizumab - purpur, tromboosi thrombocytopenic - antitrombootilised ained - cablivi on näidustatud ravi täiskasvanud kogevad episoodi omandatud tromboosi thrombocytopenic purpur (attp), koos plasma vahetus ja immunosupressiooni.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - tsüstiline fibroos - muud hingamisteede tooted - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
Eesti -
eesti -
Ecolab
01-sizzle plus heat-activated grill toaster cleaner
ecolab deutschland gmbh -